Hey all, welcome back to the Real Life Pharmacology podcast. I'm your host pharmacist, Eric Christensen.

Thank you for listening today. As always, go sign up at real life pharmacology.com. Get your free 31 page

study guide. It's on the top 200 drugs, lots of clinical practice pearls, lots of things that are going to

show up on board exams as well.

So go check that out absolutely for free, simply an email.

I'll also get you updates when we've got new podcasts and content available.

The drug of the day today is Olmosartan.

Brand name of this medication is Benicar.

And if you follow the podcast closely,

we have covered LOSARTAN in the past.

However, there definitely are some,

a couple of differences for sure that we should recognize with Olmosartin.

So I'll go through this drug individually as well. First off mechanistically,

similar to LOSARTN, it is an angio-1 and 2 receptor blocker, angiotensin 1-2 receptor blocker,

also known as an ARB, or abbreviated as ARB. Now angiotens, too, plays a role in the body by causing vasoconstriction, as well as causing elastodosterone secretion. So essentially, we are blocking

those two things. In addition, just of note, Omisartan compared to, let's say, ACE inhibitors like lysinepro, they have less Brady-Kinin effects.

So this is potentially going to lead to, or theorized, to lead to less incidence of cough as a potential side effect.

So if a patient is not taking an ACE inhibitor, they have a cough,

they still should be able to try an ARB like Olmasartin.

Uses, hypertension, ACS, proteuric renal disease.

These are definitely all common indications there.

Dosing, we've got 5, 20, and 40 milligram dosage forms.

...